Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression

Prostate

Volumn 72, Issue 4, 2012, Pages 461-467

  Keizman, Daniel ^a   Huang, Peng ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

disease progression; ketoconazole; metastatic castration resistant prostate cancer; PSA response

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL DISCOMFORT; ABDOMINAL GAS; ABDOMINAL PAIN; AGED; APPETITE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; TASTE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADRENAL GLANDS; AGED; AGED, 80 AND OVER; ANDROGENS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856053991     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21447     Document Type: Review

References (24)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI, American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605. (Pubitemid 46733088)
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042. (Pubitemid 28457865)
4. Reid AH, Attard G, Barrie E, de Bono JS,. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008; 5: 610-620.
5. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP,. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7099-7105.
6. Ang JE, Olmos D, de Bono JS,. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009; 100: 671-675.
7. Yap TA, Carden CP, Attard G, de Bono JS,. Targeting CYP17: Established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008; 8: 449-457.
8. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
9. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
10. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration resistant prostate cancer. Cancer Res 2008; 68: 6407-6415.
11. Dreicer R, Carducci M,. E-1899: An Eastern Cooperative Oncology Group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. Rev Urol 2003; 5 (Suppl 2): S35-S41.
12. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ,. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-1033. (Pubitemid 41095034)
13. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ,. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: Effect of extent of disease on outcome. J Urol 2007; 178: 2372-2376.
14. Small EJ, Baron AD, Fippin L, Apodaca D,. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-1207. (Pubitemid 27130781)
15. Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R,. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005; 173: 1947-1952. (Pubitemid 40675218)
16. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ,. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a cancer and leukemia group B study. Clin Cancer Res 2007; 13: 2030-2037. (Pubitemid 46649869)
17. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS,. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
18. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
19. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ,. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-1488.
20. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
21. de Bono J, Logothetis CJ, Fizazi K, North S, Chu L, Chi KN, Kheoh T, Haqq C, Molina A, Scher HI,. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized, double-blind, placebo-controlled phase III study. 35th ESMO Congress. 2010; Abstract LBA5.
22. Gomella LG,. Effective testosterone suppression for prostate cancer: Is there a best castration therapy? Rev Urol 2009; 11: 52-60.
23. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. (Pubitemid 29211767)
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.